We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genentech Caps Price for SMA Drug Evrysdi at $340,000 Annually
Genentech Caps Price for SMA Drug Evrysdi at $340,000 Annually
Genentech has set a maximum yearly price of $340,000 for its recently approved spinal muscular atrophy drug Evrysdi (risdiplam), making the medicine notably less expensive than the other two SMA treatments on the market.